lansoprazole has been researched along with Stomach Neoplasms in 64 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD." | 9.41 | Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023) |
| "Vonoprazan might not be superior to lansoprazole in the healing of artificial gastric ulcer after ESD." | 9.41 | Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. ( Fujiki, S; Gotoda, T; Ishiguro, M; Kawai, D; Kono, Y; Okanoue, S; Takemoto, K; Takenaka, R; Tsugeno, H, 2021) |
| "Vonoprazan efficaciously reduced the delayed bleeding rate in patients with an ESD-induced gastric ulcer." | 9.30 | Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. ( Akasaka, T; Arao, M; Fukui, K; Hamada, K; Hanaoka, N; Higashino, K; Iishi, H; Ishihara, R; Iwatsubo, T; Kanesaka, T; Kato, M; Matsuura, N; Nakahira, H; Okada, H; Shichijo, S; Shimokawa, T; Suzuki, S; Takeuchi, Y; Tonai, Y; Uedo, N; Yamamoto, S; Yamasaki, Y, 2019) |
| " In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers." | 9.20 | The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study. ( Ahn, JY; Chang, SK; Choi, CH; Han, SB; Kim, JW; Lee, JW; Park, SJ, 2015) |
| " We compared efficacy between 4 and 8 weeks of lansoprazole treatment for iatrogenic gastric ulcers that developed after ESD." | 9.19 | Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study. ( Baek, EK; Chang, SK; Choi, CH; Kim, BJ; Kim, JG; Kim, JW; Lee, KH; Park, JH, 2014) |
| "There was no significant difference between Vonoprazan and Lansoprazole in the ulcers induced by treatment after 4 weeks and 8 weeks of treatment with ESD." | 5.41 | Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. ( Bai, L; Miao, T; Wen, X; Yang, X; Zhang, Y, 2023) |
| "Vonoprazan might not be superior to lansoprazole in the healing of artificial gastric ulcer after ESD." | 5.41 | Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. ( Fujiki, S; Gotoda, T; Ishiguro, M; Kawai, D; Kono, Y; Okanoue, S; Takemoto, K; Takenaka, R; Tsugeno, H, 2021) |
| "Vonoprazan efficaciously reduced the delayed bleeding rate in patients with an ESD-induced gastric ulcer." | 5.30 | Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. ( Akasaka, T; Arao, M; Fukui, K; Hamada, K; Hanaoka, N; Higashino, K; Iishi, H; Ishihara, R; Iwatsubo, T; Kanesaka, T; Kato, M; Matsuura, N; Nakahira, H; Okada, H; Shichijo, S; Shimokawa, T; Suzuki, S; Takeuchi, Y; Tonai, Y; Uedo, N; Yamamoto, S; Yamasaki, Y, 2019) |
| "Helicobacter pylori causes chronic gastritis, gastroduodenal ulcers, and gastric cancer, and has been treated with two antibiotics (amoxicillin and clarithromycin) and proton-pump inhibitors (PPIs)." | 5.22 | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. ( Chun, J; Kim, BG; Kim, BS; Kim, JS; Kim, JW; Koh, SJ; Lee, KL; Oh, B, 2016) |
| " In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers." | 5.20 | The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study. ( Ahn, JY; Chang, SK; Choi, CH; Han, SB; Kim, JW; Lee, JW; Park, SJ, 2015) |
| " We compared efficacy between 4 and 8 weeks of lansoprazole treatment for iatrogenic gastric ulcers that developed after ESD." | 5.19 | Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study. ( Baek, EK; Chang, SK; Choi, CH; Kim, BJ; Kim, JG; Kim, JW; Lee, KH; Park, JH, 2014) |
| "Forty-eight patients with hyperplastic gastric polyps (3-10 mm in diameter) infected with H pylori were randomly assigned to a treatment group (n = 24) which received proton-pump inhibitor (omeprazole or lansoprazole), clarithromycin, bismuth citrate and tinidazole, and a control group (n = 24) which received protective agent of gastric mucosa (tepretone)." | 5.12 | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. ( Chen, JY; Ji, F; Li, YM; Ning, JW; Wang, QY; Wang, ZW, 2006) |
| " The aim of this work was to assess the gastroprotective effect of amino acid amides from imbricatolic acid and its 8(9)-en isomer in the ethanol/HCl-induced gastric lesions model in mice as well as to determine the cytotoxicity of the obtained compounds on the following human cell lines: normal lung fibroblasts (MRC-5), gastric adenocarcinoma (AGS), and liver hepatocellular carcinoma (Hep G2)." | 3.77 | Gastroprotective effect and cytotoxicity of labdeneamides with amino acids. ( Rodríguez, JA; Schmeda-Hirschmann, G; Theoduloz, C; Valderrama, JA, 2011) |
| "During a median follow-up of 9." | 2.94 | Family History of Gastric Cancer and ( Choi, IJ; Joo, J; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Park, B, 2020) |
| "Recurrence was significantly associated with study site (P = ." | 2.78 | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. ( Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M, 2013) |
| "We examined 90 patients with early gastric cancer who had undergone ESD." | 2.78 | Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. ( Asakuma, Y; Kashida, H; Kawasaki, M; Kudo, M; Matsui, S; Sakurai, T; Takayama, M, 2013) |
| "pylori-positive early gastric cancer or gastric adenoma underwent endoscopic resection and were randomly allocated to eradication or placebo group in a prospective, double-blinded, and placebo-controlled manner." | 2.78 | Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial. ( Cho, WY; Choi, IJ; Jung, HC; Keum, B; Kim, JG; Kim, SG; Lee, JH; Lee, YC; Park, BJ; Park, SK; Song, HJ, 2013) |
| "Incidence of gastric cancer in the two groups was determined based on the results of annual endoscopy and questionnaire surveys, as well as Yamagata Prefectural Cancer Registry data, and was compared between the two groups and by results of H pylori therapy." | 2.74 | Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? ( Fukase, K; Kawata, S; Mabe, K; Matsuda, T; Oizumi, H; Shibata, A; Takahashi, M; Takeda, H; Tsukuma, H, 2009) |
| "106 first-degree family members of gastric cancer patients were recruited and submitted to the 13C-urea breath test (UBT) to detect H." | 2.71 | Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients. ( Bueno, ML; Castro, LP; Coelho, LG; Lopes, LG; Martins, GM; Miranda, CH; Passos, MC; Sanches, BS, 2003) |
| "pylori associated diseases such as gastric cancer is expected." | 2.50 | [Expanded indication of National Health Insurance for H. pylori associated gastritis]. ( Kato, M, 2014) |
| "He was also diagnosed to have gastric cancer with Helicobacter pylori infection." | 2.42 | Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy. ( Arima, N; Tsudo, M, 2003) |
| "Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that is currently considered as a potential alternative to proton pump inhibitors (PPIs) for the treatment of acid-related diseases." | 1.48 | Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis. ( Fushimi, S; Horikawa, Y; Kato, Y; Mimori, N; Mizutamari, H; Okubo, S; Sato, S, 2018) |
| "The cumulative 5-year incidences of gastric cancer were 3." | 1.43 | Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. ( Fukayama, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shichijo, S; Ushiku, T; Yamada, A, 2016) |
| "Magnified findings of gastric MALT lymphoma before and after therapy seem to correlate with complete response and no response." | 1.35 | Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment. ( Asaka, M; Itoh, T; Kato, M; Kubota, K; Nakagawa, M; Ono, S; Ono, Y; Shimizu, Y, 2008) |
| "Although the possibility of preventing gastric cancer by eradicating H." | 1.35 | The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. ( Hirata, Y; Kawabe, T; Maeda, S; Mitsuno, Y; Ogura, K; Ohmae, T; Okamoto, M; Omata, M; Shibata, W; Watabe, H; Yamaji, Y; Yanai, A; Yoshida, H, 2008) |
| "Thirty of 79 rats developed gastric cancer, and they were all adenocarcinomas of the Lauren intestinal type." | 1.32 | Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux. ( Maartmann-Moe, H; Viste, A; Waldum, H; Øvrebø, K, 2004) |
| "pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels." | 1.31 | Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. ( Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (12.50) | 18.2507 |
| 2000's | 29 (45.31) | 29.6817 |
| 2010's | 22 (34.38) | 24.3611 |
| 2020's | 5 (7.81) | 2.80 |
| Authors | Studies |
|---|---|
| Miao, T | 1 |
| Zhang, Y | 1 |
| Bai, L | 1 |
| Yang, X | 1 |
| Wen, X | 1 |
| Kao, HW | 1 |
| Tsai, KW | 1 |
| Lin, WC | 1 |
| Nam, SY | 1 |
| Lee, SW | 1 |
| Jeon, SW | 1 |
| Kwon, YH | 1 |
| Lee, HS | 1 |
| Choi, IJ | 2 |
| Kim, CG | 1 |
| Lee, JY | 1 |
| Kim, YI | 1 |
| Kook, MC | 1 |
| Park, B | 1 |
| Joo, J | 1 |
| Kawai, D | 1 |
| Takenaka, R | 2 |
| Ishiguro, M | 1 |
| Okanoue, S | 1 |
| Gotoda, T | 2 |
| Kono, Y | 1 |
| Takemoto, K | 1 |
| Tsugeno, H | 1 |
| Fujiki, S | 1 |
| Horikawa, Y | 1 |
| Mizutamari, H | 1 |
| Mimori, N | 1 |
| Kato, Y | 1 |
| Fushimi, S | 1 |
| Sato, S | 1 |
| Okubo, S | 1 |
| Ishido, K | 1 |
| Tanabe, S | 1 |
| Azuma, M | 1 |
| Katada, C | 1 |
| Wada, T | 1 |
| Yano, T | 1 |
| Koizumi, W | 1 |
| Hirai, A | 1 |
| Takeuchi, T | 1 |
| Takahashi, Y | 2 |
| Kawaguchi, S | 1 |
| Ota, K | 1 |
| Harada, S | 1 |
| Kojima, Y | 1 |
| Tominaga, K | 1 |
| Tokioka, S | 1 |
| Higuchi, K | 1 |
| Hamada, K | 1 |
| Uedo, N | 1 |
| Tonai, Y | 1 |
| Arao, M | 1 |
| Suzuki, S | 2 |
| Iwatsubo, T | 1 |
| Kato, M | 5 |
| Shichijo, S | 2 |
| Yamasaki, Y | 1 |
| Matsuura, N | 1 |
| Nakahira, H | 1 |
| Kanesaka, T | 1 |
| Yamamoto, S | 1 |
| Akasaka, T | 1 |
| Hanaoka, N | 1 |
| Takeuchi, Y | 1 |
| Higashino, K | 1 |
| Ishihara, R | 1 |
| Okada, H | 2 |
| Iishi, H | 1 |
| Fukui, K | 1 |
| Shimokawa, T | 1 |
| Morgan, DR | 1 |
| Torres, J | 1 |
| Sexton, R | 1 |
| Herrero, R | 1 |
| Salazar-Martínez, E | 1 |
| Greenberg, ER | 1 |
| Bravo, LE | 1 |
| Dominguez, RL | 1 |
| Ferreccio, C | 1 |
| Lazcano-Ponce, EC | 1 |
| Meza-Montenegro, MM | 1 |
| Peña, EM | 1 |
| Peña, R | 1 |
| Correa, P | 1 |
| Martínez, ME | 1 |
| Chey, WD | 1 |
| Valdivieso, M | 1 |
| Anderson, GL | 1 |
| Goodman, GE | 1 |
| Crowley, JJ | 1 |
| Baker, LH | 1 |
| Malfertheiner, P | 1 |
| Park, JH | 1 |
| Baek, EK | 1 |
| Choi, CH | 2 |
| Lee, KH | 1 |
| Kim, BJ | 1 |
| Kim, JW | 3 |
| Kim, JG | 2 |
| Chang, SK | 2 |
| Takayama, M | 1 |
| Matsui, S | 1 |
| Kawasaki, M | 1 |
| Asakuma, Y | 1 |
| Sakurai, T | 1 |
| Kashida, H | 1 |
| Kudo, M | 1 |
| Ahn, JY | 1 |
| Lee, JW | 1 |
| Park, SJ | 1 |
| Han, SB | 1 |
| Honda, M | 1 |
| Hiki, N | 1 |
| Nunobe, S | 1 |
| Ohashi, M | 1 |
| Kumagai, K | 1 |
| Hashimoto, Y | 1 |
| Mine, S | 1 |
| Kamiya, S | 1 |
| Sano, T | 2 |
| Yamaguchi, T | 1 |
| Oh, B | 1 |
| Kim, BS | 1 |
| Kim, JS | 1 |
| Koh, SJ | 1 |
| Kim, BG | 1 |
| Lee, KL | 1 |
| Chun, J | 1 |
| Jung, YS | 1 |
| Kim, KO | 1 |
| Lee, SH | 3 |
| Jang, BI | 1 |
| Kim, TN | 1 |
| Hirata, Y | 3 |
| Niikura, R | 1 |
| Hayakawa, Y | 1 |
| Yamada, A | 1 |
| Ushiku, T | 1 |
| Fukayama, M | 1 |
| Koike, K | 1 |
| Ono, S | 1 |
| Ono, Y | 1 |
| Itoh, T | 1 |
| Kubota, K | 1 |
| Nakagawa, M | 1 |
| Shimizu, Y | 1 |
| Asaka, M | 4 |
| Fukase, K | 2 |
| Kikuchi, S | 2 |
| Inoue, K | 1 |
| Uemura, N | 1 |
| Okamoto, S | 1 |
| Terao, S | 1 |
| Amagai, K | 1 |
| Hayashi, S | 1 |
| Cheon, JH | 1 |
| Kim, JH | 1 |
| Lee, SK | 1 |
| Kim, TI | 1 |
| Kim, WH | 1 |
| Lee, YC | 2 |
| Mabe, K | 1 |
| Takahashi, M | 1 |
| Oizumi, H | 1 |
| Tsukuma, H | 1 |
| Shibata, A | 1 |
| Matsuda, T | 1 |
| Takeda, H | 1 |
| Kawata, S | 1 |
| Areche, C | 1 |
| Schmeda-Hirschmann, G | 2 |
| Theoduloz, C | 2 |
| Rodríguez, JA | 2 |
| Valderrama, JA | 1 |
| Kawano, S | 1 |
| Kawahara, Y | 1 |
| Hori, K | 1 |
| Tanioka, D | 1 |
| Tsuzuki, T | 1 |
| Inoue, M | 1 |
| Yagi, S | 1 |
| Yamamoto, K | 1 |
| Mazzoleni, LE | 1 |
| Francesconi, CF | 1 |
| Sander, GB | 1 |
| Tsukamoto, H | 1 |
| Mizoshita, T | 1 |
| Sasaki, M | 1 |
| Mizushima, T | 1 |
| Tanida, S | 1 |
| Ozeki, K | 1 |
| Shimura, T | 1 |
| Kataoka, H | 1 |
| Kamiya, T | 1 |
| Nojiri, S | 1 |
| Tsukamoto, T | 1 |
| Tatematsu, M | 1 |
| Joh, T | 1 |
| Imaeda, H | 1 |
| Hosoe, N | 1 |
| Suzuki, H | 1 |
| Saito, Y | 1 |
| Ida, Y | 1 |
| Nakamura, R | 1 |
| Iwao, Y | 1 |
| Ogata, H | 1 |
| Hibi, T | 1 |
| Lee, CK | 1 |
| Chung, IK | 1 |
| Shim, YS | 1 |
| Lee, TH | 1 |
| Kim, HS | 1 |
| Park, SH | 1 |
| Kim, SJ | 1 |
| Jianu, CS | 1 |
| Lange, OJ | 1 |
| Viset, T | 1 |
| Qvigstad, G | 1 |
| Martinsen, TC | 1 |
| Fougner, R | 1 |
| Kleveland, PM | 1 |
| Fossmark, R | 1 |
| Hauso, Ø | 1 |
| Waldum, HL | 1 |
| Kim, SG | 1 |
| Song, HJ | 1 |
| Cho, WY | 1 |
| Lee, JH | 1 |
| Keum, B | 1 |
| Park, SK | 1 |
| Park, BJ | 1 |
| Jung, HC | 1 |
| Coelho, LG | 2 |
| Martins, GM | 2 |
| Passos, MC | 2 |
| Bueno, ML | 2 |
| Sanches, BS | 1 |
| Lopes, LG | 2 |
| Miranda, CH | 1 |
| Castro, LP | 2 |
| Arima, N | 1 |
| Tsudo, M | 1 |
| Takahashi, S | 2 |
| Hamaguchi, K | 1 |
| Ogawa, K | 1 |
| Katsube, T | 1 |
| Konno, S | 1 |
| Aiba, M | 1 |
| Viste, A | 1 |
| Øvrebø, K | 1 |
| Maartmann-Moe, H | 1 |
| Waldum, H | 1 |
| de Mascarel, A | 2 |
| Ruskone-Fourmestraux, A | 2 |
| Lavergne-Slove, A | 1 |
| Megraud, F | 2 |
| Dubus, P | 1 |
| Merlio, JP | 1 |
| Attila, T | 1 |
| Santharam, R | 1 |
| Blom, D | 1 |
| Komorowski, R | 1 |
| Koch, TR | 1 |
| Ji, F | 1 |
| Wang, ZW | 1 |
| Ning, JW | 1 |
| Wang, QY | 1 |
| Chen, JY | 1 |
| Li, YM | 1 |
| Katsuyama, T | 1 |
| Tominaga, S | 1 |
| Handa, O | 1 |
| Yoshida, N | 1 |
| Fujita, N | 1 |
| Tanaka, Y | 1 |
| Ueda, M | 1 |
| Takagi, T | 1 |
| Kokura, S | 1 |
| Naito, Y | 1 |
| Okanoue, T | 1 |
| Yoshikawa, T | 1 |
| Bertoli Neto, JL | 1 |
| Lourenço, LG | 1 |
| Bertoli, CF | 1 |
| Ulbrich, FS | 1 |
| Sabbi, AR | 1 |
| Bueno, AG | 1 |
| Chen, ZM | 1 |
| Shah, R | 1 |
| Zuckerman, GR | 1 |
| Wang, HL | 1 |
| Romero-Gallo, J | 1 |
| Harris, EJ | 1 |
| Krishna, U | 1 |
| Washington, MK | 1 |
| Perez-Perez, GI | 1 |
| Peek, RM | 1 |
| Ogura, K | 1 |
| Yanai, A | 1 |
| Shibata, W | 1 |
| Ohmae, T | 1 |
| Mitsuno, Y | 1 |
| Maeda, S | 1 |
| Watabe, H | 1 |
| Yamaji, Y | 1 |
| Okamoto, M | 1 |
| Yoshida, H | 1 |
| Kawabe, T | 1 |
| Omata, M | 1 |
| Watari, J | 1 |
| Das, KK | 1 |
| Amenta, PS | 1 |
| Tanabe, H | 1 |
| Tanaka, A | 1 |
| Geng, X | 1 |
| Lin, JJ | 1 |
| Kohgo, Y | 1 |
| Das, KM | 1 |
| Matsui, H | 1 |
| Aikawa, C | 1 |
| Sekiya, Y | 1 |
| Murayama, SY | 1 |
| Nakamura, M | 1 |
| Arnold, R | 1 |
| Seko, A | 1 |
| Amano, K | 1 |
| Shimizu, H | 1 |
| Takagi, S | 1 |
| Goto, A | 1 |
| Kondo, H | 2 |
| Sugie, S | 1 |
| Yoshimi, N | 1 |
| Moriwaki, H | 1 |
| Muto, Y | 1 |
| Matsunaga, K | 1 |
| Oofukuji, M | 1 |
| Syukuwa, S | 1 |
| Osabe, M | 1 |
| Takeno, Y | 1 |
| Isomoto, H | 1 |
| Mizuta, Y | 1 |
| Kohno, S | 1 |
| Ohtsu, T | 1 |
| Boku, N | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Ohkusa, T | 1 |
| Takashimizu, I | 1 |
| Fujiki, K | 1 |
| Shimoi, K | 1 |
| Horiuchi, T | 1 |
| Sakurazawa, T | 1 |
| Ariake, K | 1 |
| Ishii, K | 1 |
| Kumagai, J | 1 |
| Tanizawa, T | 1 |
| Saito, D | 1 |
| Ono, H | 1 |
| Oda, I | 1 |
| Fujishiro, M | 1 |
| Yamaguchi, H | 1 |
| Gomes, BS | 1 |
| Begum, S | 1 |
| Endo, H | 1 |
| Kawamata, H | 1 |
| Urakami, Y | 1 |
| Weinstein, WM | 1 |
| Lavergne, A | 1 |
| Aegerter, PH | 1 |
| Palazzo, L | 1 |
| Molina, T | 1 |
| Rambaud, JL | 1 |
| Miki, H | 1 |
| Kobayashi, S | 1 |
| Harada, H | 1 |
| Yamanoi, Y | 1 |
| Uraoka, T | 1 |
| Sotozono, M | 1 |
| Ohmori, M | 1 |
| Kato, K | 1 |
| Sugitani, M | 1 |
| Nagata, T | 1 |
| Nishinarita, S | 1 |
| Kawamura, F | 1 |
| Ishii, Y | 1 |
| Kawamura, Y | 1 |
| Komuro, S | 1 |
| Yanai, M | 1 |
| Nemoto, N | 1 |
| Arakawa, Y | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Mulder, CJ | 1 |
| Nusteling, K | 1 |
| Salam, I | 1 |
| Durai, D | 1 |
| Murphy, JK | 1 |
| Sundaram, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)[NCT03065868] | Phase 4 | 32 participants (Actual) | Interventional | 2015-12-09 | Completed | ||
| Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study[NCT01678027] | Phase 3 | 1,838 participants (Actual) | Interventional | 2004-11-30 | Active, not recruiting | ||
| A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori[NCT01061437] | Phase 3 | 1,859 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Prediction for the Development of Metachronous Gastric Cancer After Endoscopic Submucosal Dissection by Serum Pepsinogen[NCT02682446] | 800 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents (PROTOCOL)[NCT05817721] | 639 participants (Anticipated) | Observational | 2023-05-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for lansoprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis.
Topics: Endoscopic Mucosal Resection; Humans; Lansoprazole; Proton Pump Inhibitors; Stomach Neoplasms; Stoma | 2023 |
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gast | 2014 |
Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Clarithromycin; Drug The | 2003 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gas | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Proton pump inhibitors and H. pylori infection: why the concern?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastritis, Atrophic; | 1999 |
27 trials available for lansoprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial.
Topics: Adenomatous Polyps; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitorin | 2020 |
Family History of Gastric Cancer and
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug | 2020 |
Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.
Topics: Dissection; Endoscopic Mucosal Resection; Humans; Lansoprazole; Prospective Studies; Proton Pump Inh | 2021 |
Comparison of oral and intravenous lansoprazole for the prevention of bleeding from artificial ulcers after endoscopic submucosal dissection for gastric tumors: a prospective randomized phase II study (KDOG 0802).
Topics: Administration, Oral; Aged; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Hemos | 2018 |
Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Lansoprazole; Male; | 2018 |
Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study.
Topics: Aged; Endoscopic Mucosal Resection; Female; Hematemesis; Hemoglobins; Humans; Lansoprazole; Male; Me | 2019 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath | 2013 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2013 |
Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dissection; Drug Administration Schedule; Endosco | 2014 |
Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.
Topics: Adenocarcinoma; Aged; Alanine; Anti-Ulcer Agents; Dissection; Female; Gastroscopy; Humans; Iatrogeni | 2013 |
The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study.
Topics: Abietanes; Aged; Anti-Ulcer Agents; Dissection; Drug Therapy, Combination; Endoscopy, Gastrointestin | 2015 |
Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2015 |
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA, Ribosomal; Drug Therapy, Combination; Femal | 2016 |
[Comparison on Oral versus Intravenous Proton Pump Inhibitors for Prevention of Bleeding after Endoscopic Submucosal Dissection of Gastric Lesions].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anticoagulants; Endoscopic Muco | 2016 |
Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Clarithromycin; Endoscopy, Gas | 2008 |
Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2008 |
Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cost-Benefit Analysis; Female; Gas | 2011 |
Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost-Benefit An | 2011 |
Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers: a retrospective analysis and prospective validation study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dissection; Endoscopy, Gastrointestinal; Enzyme Inhib | 2012 |
Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Met | 2013 |
Once-daily, low-cost, highly effective Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Ag | 2003 |
Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2006 |
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2006 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; | 1998 |
Once-daily Helicobacter pylori treatment to family members of gastric cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Dose-Response Rel | 2000 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
31 other studies available for lansoprazole and Stomach Neoplasms
| Article | Year |
|---|---|
Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Lansoprazole; Metformin; Proton Pump Inhibitors; Stomach | 2023 |
Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis.
Topics: Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Humans; Japan; Lansoprazole; Logistic | 2018 |
Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Breath Tests; Clarithromycin; Cohort Studies; Fem | 2016 |
Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2008 |
Gastroprotective effect and cytotoxicity of abietane diterpenes from the Chilean Lamiaceae Sphacele chamaedryoides (Balbis) Briq.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adenocarcinoma; Animals; Anti-Ulcer Agents; Anti | 2009 |
Gastroprotective effect and cytotoxicity of labdeneamides with amino acids.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Amides; Amino Acids; Animals; Anti-Ulcer Ag | 2011 |
Mass eradication of Helicobacter pylori: feasible and advisable?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2011 |
Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Carcinoma; Cell Transformation, Neoplastic; Chromo | 2011 |
Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Carcinoma, Neuroendocrine; Chromogranin A; Gastrins; Gastro | 2012 |
Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Anti-Bacterial Agents; A | 2004 |
Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Administration, Oral; Animals; Duodenogastr | 2004 |
Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Th | 2005 |
Multifocal gastric carcinoid tumor in a patient with pernicious anemia receiving lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anemia, Pernicious; Biopsy, Needle; Carcinoid Tumor; Female | 2005 |
Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents; Calcium; Cell Line, Tumor; Cell M | 2006 |
Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Ag | 2006 |
Epstein-Barr virus gastritis: an underrecognized form of severe gastritis simulating gastric lymphoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Diagnosis, Differential; Endoscopy, | 2007 |
Effect of Helicobacter pylori eradication on gastric carcinogenesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Amoxicillin; Animals; Animals, Outbred Stra | 2008 |
The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents | 2008 |
Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective | 2008 |
Evaluation of antibiotic therapy for eradication of "Candidatus Helicobacter heilmannii".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Drug Therapy, | 2008 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Co | 1997 |
[Successful eradication of H. pylori in an elderly patient with gastric cancer after effective UFT-E therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Ba | 1997 |
[Gastric lymphoma--a case report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Gastrosc | 1998 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; A | 1999 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female | 2000 |
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2001 |
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; D | 2001 |
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Drug Therapy, | 2001 |
Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Helicobacter Infections; Helicobacter pylori; | 2001 |